

Influenza, RSV and COVID-19 Enhanced Surveillance Critical Care – Adult

		Admission F	orm			hoss
lhmeannacht na Seirbhíse Sláinte Health Service Executive	C S Intens	sive Care Societ	y of Ireland		•	hpsc
Forename Surn	ame		MRN		Sex: Female	Male
DOB: Age:	Weigh	t	kg Height [m BMI	Kg/m2
HSE area of Residence	County	of Residence	Co	ountry of Residence	ce	
Country of birth	Ethnici	ty		ccupation		
GP Name	_		es No	Unknow	n	
GP Telephone	GP Add	Iress				
All information completed on t	his form should	relate to the patie	ent's admission to	THIS hospital, no	nt referring hospit	cal
Name hospital						
Date of hospital admission	is hospital	Date of admission Ware OR Emer		nt		
From another	hospital	OR Non-I		Name of hospital		
Clinical Details						
Was COVID-19 infection the primary cause of Yes No, contributory factor	ICU admission	as clinically asses Not applicable (if				
If the answer is "no" or "no contributory fact RSV cases Please select organisms that apply	tor", there is no	requirement to o	complete this for	m. Please comple	ete the form for i	nfluenza and
SARS-CoV-2 (COVID-19) Influenza A (not subtyped) Influenza A (H1) pdm 2009 Respiratory syncytial virus (RSV)						
Co-infected with iGAS Yes No Unknown Co-infected with RSV Yes No Unknown Date of onset of symptoms						
Was the infection determined to be hospital Influenza Vaccine Status	acquired?	Yes No	Unknow	n		. 1
Vaccinated against influenza	No U	nknown	Date of influe	nza vaccination:		
Influenza vaccine type (if available) LAIV (nasal) ¹ QIV ² Other Unknown						
COVID-19 Vaccine Status Vaccinated against COVID-19 (any dose)	es 📗 I	No Unkno	wn Nur	mber of doses		
	SOFA scor	e on admiss	ion to this IC	CU		
Parameter	0	1	2	3	4	Total
[PaO ₂ kPa /FiO ₂] ratio*	> 40	30-39	20-29	10-19	< 10	
Platelet count (10 ⁶ /L) Bilirubin (umol/L)	>150 < 20	≤150 20-32	≤ 100 33-100	≤ 50 101-203	≤ 20 > 203	
Hypotension	MAP > 70mmHg	MAP < 70mmHg	Dop ≤ 5 or equivalent	Dop >5 or Epi ≤ 0.1 or Norepi ≤ 0.1	Dop > 15 or Epi > 0.1 or Norepi > 0.1	
GCS	15	13-14	10-12	6-9	< 6	
Serum Creatinine* (umol/L)	< 106	107-168	169-300	301-433	> 434	
Total Does the patient have Acute Respiratory Dis Does the patient require non-invasive advar Does the patient require invasive mechanica Does the patient require renal replacement	ced respiratory I ventilation on	support (CPAP, B admission?	iPAP or HFNO) or	Yes n admission? Yes Yes Yes	No No No No	*See Definitions - page 4
Comments	<u> </u>					
¹ LAIV refers to Live Attenuated Influenza Vac ² QIV refers to Quadrivalent Influenza Vaccine						

Date

Underlying Medica Underlying medical condition	Yes	No	Unknown
Does the case have any underlying medical			
conditions? Chronic heart disease			
Hypertension			
Chronic kidney disease			
Chronic liver disease			
Chronic neurological disease			
Cancer/malignancy including hematological ¹			
-			
mmunodeficiency/Immunosuppression			
Due to HIV			
Due to Solid Organ Transplantation			
Due to Therapy (chemotherapy, radiotherapy, high dose steroids, immunomodulators, anti-TNF agents, etc. (see definitions pg 4)			
Due to Primary immunodeficiency (see definitions pg4)			
Due to inherited metabolic disorders			
Due to asplenia or hyposplenia			
Chronic respiratory disease including:			
Chronic obstructive pulmonary disease (COPD) (including chronic bronchitits and emphysema) Bronchiectasis			
Cystic fibrosis			
Interstitial lung fibrosis			
Asthma (requiring medication)			
Mild to moderate			
Severe (uncontrolled despite proper medication and treatment)			
Other			
Pregnant			
Week of gestation		_	_
Is the case <= 6 weeks post partum			
Diabetes mellitus			
Type I			
Type II			
Gestational diabetes			
Hypothyroidism			
Haemoglobinopathy			
Alcohol related disease			
Other			
underlying medical conditions, please specify:			
tatus: Current smoker Never smoked	Former smoker (sto	pped smoking ≥ 1 year aş	go) Unknov



Influenza, RSV and COVID-19 Enhanced Surveillance Critical Care - Adult

Part 2 – Discharge Form

			_			
cs	Intensive	Care	Society	of	Irelan	a

Patient Details All information completed on this form should relate to the patient's curr	ent ICU admission	
Forename Surname	CIDR Event ID	5UDCC
DOB MRN MRN		For HPSC use only
Name hospital ————————————————————————————————————		
Date of discharge from ICU Length of stay in ICU (days)		
Clinical complications		
Please tick all that apply Yes No	Yes No	
Primary viral pneumonia Myocarditis		
Secondary bacterial pneumonia Encephalitis		¹ See AKI Definition on page 4
Acute Respiratory Distress Syndrome ² Acute kidney injury ¹		² See Berlin ARDs and AKI definitions on page 4 ³ See ICNARC definition on
Multiorgan failure ³		page 4
Treatment intervention		
Antivirals commenced Yes No Unknown Date antiviral treatment	ent commenced	
Oseltamivir Yes No Unknown If other antiviral used	d please name	
Pressor dependence at any time Yes No Required Anticoagulation Treatment for a Thrombot	Yes [No No
CRRT/IHD Yes No	ic Event	
Non-invasive advanced respiratory support (CPAP, HFNO or BiPAP) Yes No	I I	1 1
CPAP/HFNO ventilation Duration CPAP/HFNO ventilation Duration BiPAP ventilation (date)	1 1	
BiPAP ventilation		
Invasive mechanical ventilation Yes No		
Conventional (including lung protective) mechanical ventilation Duration conv	entional MV (days)	
ECMO Duration ECM	O (days)	
Discharge Information		
Transferred from ICU to: Ward Other Ward HDU Other HDU Other Ward If transferred to other ICU, please state name	* ICU ECMO	abroad Died
If patient transferred to different hospital for ECMO, please state hospital		
Deaths		
If died, date of death:		
Is influenza a likely cause of death? Yes No Unknown	Not applicable	
Is COVID-19 a likely cause of death? Yes No Unknown	Not applicable	
Is RSV a likely cause of death? Yes No Unknown	Not applicable	·
Coroner's case Yes No Unknown	Not applicable	<u>. </u>
Comments		
Signature Date		





Definitions

ARDS - Acute Respiratory Distress Syndrome

- Berlin Criteria

- Include all ARDS – mild, moderate and severe

Timing Within 1 week of a known clinical insult or new/worsening respiratory symptoms

Chest Imaging* Bilateral opacities not fully explained by effusion, lobar/lung collapse or nodules

Origin of oedema Respiratory failure not fully explained by cardiac failure of fluid overload

Needs objective assessment (e.g echocardiography) to exclude hydrostatic oedema if

no risk factor present

Oxygenation Mild -26.6kPa < PaO₂/FiO₂ = 39.9 kPa

Moderate -13.3kPa < PaO₂ / FiO₂ = 26.6 kPa

Severe $-PaO_2/FiO_2 = 13.3 \text{ kPa}$

PEEP or CPAP = 5cmH2 all above

e.g if PaO2 = 20 kPa and FiO2 = 0.5 then Paos/FiO2 ratio = 20/0.5 = 40.

Acute Kidney Injury

Use AKI classification

Stage	Creatinine Criteria Urine output criteria		Urine output criteria
1	Cr. x 1.5–2 from baseline	or	<0.5 ml/kg/hr for 6 hours
2	Cr. x 2-3 from baseline	or	<0.5 ml/kg/hr for 12 hours
3	Cr. x3 from baseline Or Cr? 354 umol/l with an acute rise > 44 umol/l or need RRT	or	< 0.3 ml/kg/hr for 24 hours or anuria for 12 hours or need for RRT

Multi organ failure

Using ICNARC definition

ICNARC define level 3 care as patients requiring organ support for two or more organ systems, excluding gastrointestinal support.

Immunodeficiency/Immunosuppression

Due to therapy	The following dose of prednisolone (or equivalent dose of other glucocorticoid) are likely to be immunosuppressive. Adults and children = 10kg: =40mg/day for more than 1 week or= 20mg/day for 2 weeks or longer; Children <10kg: 2mg/kg/day for 2 weeks or longer.
	Azathioprine, cyclophosphamide, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, mycophenolic acid preparations, sirolimus and tacrolimus, in addition to biologics such as TNF α blocking agents (adalimumab, etanercept, infliximab), and others including abatacept, anakinra, eculizumab, rituximab and tocilizumab.
Due to primary immunodeficiency	Ataxia Telangiectasia; Bruton agammaglobulinemia (X linked agammaglobulinemia, XLA), Chronic granulomatous disease (CGD), Chronic mucocutaneous candidiasis (APECED syndrome), Complement deficiency, Common variable immunodeficiency (CVID) & other immunoglobulin deficiencies, DiGeorge syndrome, Down syndrome, Fanconi's anaemia, Wiskott Aldrich Syndrome, Severe combined immunodeficiency syndrome (SCID).

^{*}chest radiograph or CT ref.table modified from BJA Education, Vol 17 Number 5 2017

^{*} FiO2 = inspired O2 concentration as a fraction of 1 (1=100% O2, 0.5 = 50% O2)